Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Eiger Biopharmaceuticals (EIGRQ) has provided an update.
William G. Kachioff is stepping down as Chief Financial Officer of Eiger BioPharmaceuticals, effective April 29, 2024, amidst the company’s ongoing Chapter 11 bankruptcy proceedings. Following his departure, Eiger BioPharmaceuticals is increasing its reliance on financial advisory firm Alvarez & Marsal, appointing its managing director Douglas Staut as Chief Restructuring Officer. Investors are warned that trading the company’s securities is highly speculative and risky, with the potential for significant or total investment losses, depending on the resolution of the bankruptcy case.
For an in-depth examination of EIGRQ stock, go to TipRanks’ Stock Analysis page.
